Table 1.
Monoclonal antibodies approved for clinical use and SARS-CoV-2 variant evasion of neutralization
| Generic name | Other name | Manufacturer | mAb class | Spike epitopea | VOC resistanceb |
|---|---|---|---|---|---|
| Amubarvimab + romlusevimab85,86 | BRII-196 + BRII-198, P2C-1F11 + P2B-1G5 | Brii Biosciences |
Amubarvimab: class 1 Romlusevimab: no data |
Amubarivimab: 403, 415, 416, 417, 420, 421, 453, 455, 456, 457, 458, 459, 460, 473, 474, 475, 476, 477, 486, 487, 489, 493, 502, 505 Romlusevimab: no data |
Strong: BA.1.1, BA.4/5 Moderate: BA.1, BA.2, BA.2.12.1 |
| Bamlanivimab10 (withdrawn) | LYCoV555, LY3819253 | Eli Lilly | Class 2 | 351, 449, 450, 452, 455, 456, 470, 472, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 492, 493, 494 | Strong: Beta, Gamma, Delta, BA.1, BA.1.1, BA.2, BA.2.12.1, BA.4/5 |
| Bamlanivimab + etesevimab13,87,88 | Etesevimab: LY3832479, LY-CoV016 (see bamlanivimab) | Eli Lilly |
Etesevimab: class 1 Bamlanivimab: class 2 |
Etesevimab: 403, 405, 406, 408, 409, 415, 416, 417, 420, 421, 455, 456, 457, 458, 459, 460, 473, 474, 475, 476, 477, 486, 487, 489, 493, 494, 495, 500, 501, 502, 504, 505 (see bamlanivimab) | Strong: Beta, Gamma, BA.1, BA.1.1, BA.2, BA.2.12.1, BA.4/5 |
| Bebtelovimab89 | LY-CoV1404, LY3853113 | Eli Lilly | Class 3 | 346, 439, 440, 441, 443, 444, 445, 446, 447, 448, 449, 450, 498, 499, 500, 501, 502, 506, 509 | |
| DXP-604 (ref.90) | NA | Singlomics + BeiGene | Class 1 | 403, 415, 416, 417, 420, 421, 453, 455, 456, 457, 458, 459, 460, 473, 474, 475, 476, 477, 486, 487, 489, 493, 496, 498, 500, 501, 502, 503, 505 |
Moderate: BA.1 Mild: Beta |
| Regdanvimab91 | Regkirona, CT-P59 | Celltrion Healthcare | Class 1 | 351, 403, 417, 446, 449, 450, 452, 453, 455, 456, 470, 483, 484, 485, 486, 489, 490, 492, 493, 494, 495, 496, 498, 505 |
Strong: BA.1, BA.2, BA.1.1 Moderate: Beta, Delta, Gamma |
| Ronapreve12,92 | REGEN-CoV2, casirivimab + imdevimab | Regeneron |
Casirivimab: class 1 Imdevimab: class 3 |
Casirivimab: 403, 417, 421, 453, 455, 456, 475, 476, 484, 485, 486, 487, 488, 489, 493 Imdevimab: 346, 439, 440, 441, 444, 445, 446, 447, 448, 449, 450, 498, 500 |
Strong: BA.1, BA.1.1, BA.2, BA.2.12.1, BA.4/5 |
| Sotrovimab11,93,94 |
Xevudy, VIR-7831, GSK4182136 Parental antibody: S309 |
GlaxoSmith-Kline | Class 3 | 333, 334, 335, 337, 339, 340, 343, 344, 345, 346, 354, 356, 357, 359, 360, 361, 441, 509 |
Moderate: BA.2, BA.2.12.1, BA.4/5 Mild: BA.1 |
| Cilgavimab + tixagevimab95–97 |
Evusheld AZD7442, AZD1061/AZD8895 Parental antibodies: COV2-2130, COV2-2196 |
AstraZeneca |
Tixagevimab: class 1 Cilgavimab: class 2 |
Tixagevimab: 455, 456, 458, 475, 476, 477, 478, 479, 484, 485, 486, 487, 488, 489, 493 Cilgavimab: 345, 346, 439, 440, 441, 443, 444, 445, 446, 447, 448, 449, 450, 452, 484, 490, 492, 493, 494, 499 |
Strong: BA.1.1 Moderate: BA.1, BA.2.12.1, BA.4/5 Mild: BA.2 |
mAb, monoclonal antibody; mFRN, geometric mean fold reduction in neutralization; NA, not available; VOC, variant of concern. aEpitope positions are defined as those within 4.5 Å of the mAb when it is bound to the spike protein. bVOC strength of resistance is reported as strong (mFRN > 100), moderate (mFRN = 10–100) or mild (mFRN = 3–10), based on the data reported in Fig. 1. Although these designators are useful to the extent that they assign a qualitative judgement to the level of resistance, it must be emphasized that resistance of variants occurs across a continuum.